AMENDED AND RESTATED COMMERCIALIZATION AGREEMENT Dated October 31, 2023Commercialization Agreement • March 28th, 2024 • Atara Biotherapeutics, Inc. • Biological products, (no disgnostic substances)
This Amended and Restated Commercialization Agreement (this “Agreement”) is made as of October 31, 2023 (the “Execution Date”), by and between Atara Biotherapeutics, Inc., incorporated under the laws of Delaware and having its registered office at 2380 Conejo Spectrum Street, Suite 200, Thousand Oaks, CA 91320 (“Atara”), and Pierre Fabre Medicament, having its registered office at les Cauquillous, 81500 Lavaur, France (“Partner”). Atara and Partner are referred to in this Agreement individually as a “Party” and collectively as the “Parties.”
AMENDMENT NO. 6 TO COMMERCIAL MANUFACTURING SERVICES AGREEMENTCommercial Manufacturing Services Agreement • March 28th, 2024 • Atara Biotherapeutics, Inc. • Biological products, (no disgnostic substances)
This Amendment No. 6 to the Commercial Manufacturing Services Agreement (“Sixth Amendment”) is made, entered into and effective as of December 30, 2023 (the “Sixth Amendment Effective Date”) by and between ATARA BIOTHERAPEUTICS, INC., a Delaware corporation with offices at 2380 Conejo Spectrum Street, Suite 200, Thousand Oaks, CA 91320 (“Atara”); and CHARLES RIVER LABORATORIES, INC. (successor in interest to COGNATE BIOSERVICES INC.), a Delaware corporation with offices at 4600 East Shelby Drive, Suite 108, Memphis, TN 38118 (“Manufacturer”). Each of Atara and Manufacturer are referred to in this Sixth Amendment as a “Party” and together, the “Parties.” All capitalized terms used, but not otherwise defined herein, shall have the same meaning ascribed to them in the Commercial Services Agreement (as defined below).
AMENDMENT NO. 7 TO COMMERCIAL MANUFACTURING SERVICES AGREEMENTCommercial Manufacturing Services Agreement • March 28th, 2024 • Atara Biotherapeutics, Inc. • Biological products, (no disgnostic substances)
This Amendment No. 7 to the Commercial Manufacturing Services Agreement (“Seventh Amendment”) is made, entered into and effective as of January 31, 2024 (the “Seventh Amendment Effective Date”) by and between ATARA BIOTHERAPEUTICS, INC., a Delaware corporation with offices at 2380 Conejo Spectrum Street, Suite 200, Thousand Oaks, CA 91320 (“Atara”); and CHARLES RIVER LABORATORIES, INC. (successor in interest to COGNATE BIOSERVICES INC.), a Delaware corporation with offices at 4600 East Shelby Drive, Suite 108, Memphis, TN 38118 (“Manufacturer”). Each of Atara and Manufacturer are referred to in this Seventh Amendment as a “Party” and together, the “Parties.” All capitalized terms used, but not otherwise defined herein, shall have the same meaning ascribed to them in the Commercial Services Agreement (as defined below).
